Table 1.
Phase III randomized trials of platin-based doublets
| Reference | Patients | Treatment | RR (%) | OS (mo) | 1 Year (%) | P (OS) |
|---|---|---|---|---|---|---|
| Kelly16 | 408 | VNR/CDDP | 28 | 8.1 | 36 | |
| CBDCA/PAC | 25 | 8.6 | 38 | 0.87 | ||
| Rosell17 | 618 | PAC/CDDP | 28 | 9.8 | 38 | |
| PAC/CBDCA | 25 | 8.2 | 33 | 0.019 | ||
| Scagliotti18 | 612 | GEM/CDDP | 30 | 9.8 | 37 | |
| CBDCA/PAC | 32 | 9.9 | 43 | 0.484a | ||
| VNR/CDDP | 30 | 9.5 | 37 | 0.105a | ||
| Ohe19 | 602 | CDDP/CPT-11 | 31 | 13.9 | 59.2 | |
| CBDCA/PAC | 32.4 | 12.3 | 51 | 0.465 | ||
| CDDP/GEM | 30.1 | 14 | 59.6 | 0.949 | ||
| CDDP/VNR | 33.1 | 11.4 | 48.3 | 0.242 | ||
| Schiller15 | 1207 | PAC/CDDP | 21 | 7.8 | 31 | |
| GEM/CDDP | 22 | 8.1 | 36 | NSb | ||
| DOC/CDDP | 17 | 7.4 | 31 | NS | ||
| CBDCA/PAC | 17 | 8.1 | 34 | NS | ||
| Fossella4 | 1218 | VNR/CDDP | 24.5 | 10.1 | 41 | |
| DOC/CDDP | 31.6 | 11.3 | 46 | 0.044 | ||
| VNR/CDDP | 24.5 | 9.9 | 40 | |||
| DOC/CBDCA | 23.9 | 9.4 | 38 | 0.657 |
Notes: If more than two regimens were compared in one study, the topmost regimen was the reference regimen and P value is based on comparison to the reference regimen.
a
P value for 1-year survival rate.
b
P value was not reported.
Abbreviations: RR, response rate; OS, overall survival; 1 Yr, one-year survival; VNR, vinorelbine; CDDP, cisplatin; CBDCA, carboplatin; PAC, paclitaxel; GEM, gemcitabine; CPT-11, irinotecan; DOC, docetaxel; NS, not significant.